The number of patients treated with TKI before and after transplantation was 17 (77.3%) and five (25.0%) in the AML with BCR::ABL1 group and seven (77.8%) and one (16.7%) in the MPAL with BCR::ABL1 group, respectively. This evidence concerns the gene BCR and acute myeloid leukemia.